Company Updates

10/10/2013 “Moggie Mining Limited (“MML”) is seeking to raise $2.0 million to assist with a comprehensive drilling and exploration programme on its mining tenements situated near Greenvale, North Queensland. There are strong indications available to MML of the presence in those tenements of large porphyry copper/gold deposits of a dimension capable of supporting commercial mining […]

8 October 2013 Always being innovative and able to listen to the market, Cloud DC is to release its next offering, SandBox. Cloud DC has recognised that by stripping out the DNA, or building blocks of its flagship product OfficeBox, they can deliver the ultimate Platform as a Service (PaaS). Cloud DC gives you the […]

Open to opportunity: Sandon founder Gabriel Radzyminski. Photo: Andrew Quilty Source: AFR , Stephen Shore Gabriel Radzyminski, the man behind several high-profile activist plays on the sharemarket over the past few years, is preparing to list his own fund, Sandon Capital Investments, on the Australian Securities Exchange. Mr Radzyminski, who also sits on the board of Ron […]

Patent for anti-midkine antibodies to prevent and treat cancer, inflammatory and autoimmune diseases granted in Europe Most important patent family in Cellmid’s cancer treatment program Second granted patent in global patent family SYDNEY, Tuesday, 8 October 2013: Cellmid Limited (ASX: CDY) advises that the European Patent Office has granted one of Cellmid’s most important antibody […]

Three exploration work programs separately targeting economic copper, gold and nickel currently underway Field component of 3,000 metre copper RC drill program completed at the East Arunta Project with all results to be received within next 2 – 3 weeks 2,400 metre nickel RC drill program currently underway with an additional aeromagnetic survey to identify […]

SYDNEY, Friday, 04 October 2013: Cellmid Limited (ASX: CDY) advises that it has received $711,895.35 refund under the Federal Government’s R&D Tax Incentive Scheme. The tax refund relates to the cost of research and development conducted by the Company on its midkine technology portfolio during the 2013 financial year and was calculated as 45% of […]

Anti-midkine antibodies reduce tumour growth and spread Anti-angiogenic mechanism of action also evident Final studies in the programme to determine Cellmid’s clinical direction SYDNEY, Thursday, 03 October 2013: Cellmid Limited (ASX: CDY) is pleased to advise that it has now completed its several cancer xenograft efficacy and mechanism of action studies using the company’s lead […]

By: Steve Robinson Chief Executive Officer, Cloud Data Centre Ltd Cloud DC’s flagship product OfficeBox gives you the tools to take your entire Office IT environment anywhere, any time and on any device. This has been now proven even more so with Cloud DC today announcing that OfficeBox also runs seamlessly on the new Amazon […]